This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/AHFS/
n17http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n11http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/patent/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/national-drug-code-directory/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n25http://linked.opendata.cz/resource/drugbank/property/
n8http://www.rxlist.com/cgi/generic2/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/genbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00053/identifier/uniprotkb/
n26http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00053
rdf:type
n4:Drug
n4:description
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues
n4:dosage
n9:271B4258-363D-11E5-9242-09173F13E4C5
n4:generalReferences
# Pastores GM, Hughes DA: Gaucher Disease "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20301446
n4:group
approved
n4:halfLife
3.6-10.4 min
n4:indication
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
n4:manufacturer
n17:271B4254-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00053 n20:DB00053
dcterms:title
Imiglucerase
adms:identifier
n6:DB00053 n15:P04062 n16:58468-4663-1 n19:M16328 n21:D02810 n22:Imiglucerase n23:PA164742934
n4:mechanismOfAction
Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.
n4:packager
n17:271B4253-363D-11E5-9242-09173F13E4C5
n4:patent
n18:5549892
n4:volumeOfDistribution
* 0.09 to 0.15 L/kg
n13:hasAHFSCode
n14:44-00-00
foaf:page
n8:imiglucerase.htm n12:imiglucerase.html
n4:Molecular-Formula
n25:271B425C-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n25:271B425B-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n26:A16AB02
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
143003-46-7
n4:category
n4:clearance
* 14.5 +/- 4.0 mL/min/kg
n4:containedIn
n24:271B4257-363D-11E5-9242-09173F13E4C5 n24:271B4255-363D-11E5-9242-09173F13E4C5 n24:271B4256-363D-11E5-9242-09173F13E4C5
n4:Hydrophobicity
n25:271B4259-363D-11E5-9242-09173F13E4C5
n4:Isoelectric-Point
n25:271B425A-363D-11E5-9242-09173F13E4C5